Market revenue in 2023 | USD 3,545.7 million |
Market revenue in 2030 | USD 9,332.7 million |
Growth rate | 14.8% (CAGR from 2023 to 2030) |
Largest segment | Therapeutics |
Fastest growing segment | Banks |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Therapeutics, Tools, Banks, Services |
Key market players worldwide | AstraZeneca PLC, Roche Holding AG, Integra Lifesciences Holdings Corp, Astellas Pharma Inc, Cook Group, Bayer AG, Pfizer Inc, Merck KGaA, Abbott Laboratories, Vericel Corp, Novartis AG ADR, GlaxoSmithKline |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to regenerative medicine market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 76.77% in 2023. Horizon Databook has segmented the Asia Pacific regenerative medicine market based on therapeutics, tools, banks, services covering the revenue growth of each sub-segment from 2018 to 2030.
The regenerative medicine market in the Asia Pacific is expected to witness significant growth over the forecast period due to increasing investments in regenerative medicine areas and increasing focus of players on regional penetration for cell therapy, gene therapy, and tissue-based therapies. For instance, Takara Bio a Japan-based company is a major player in gene therapy. In May 2020, the company expanded its Center for Gene and Cell Processing by constructing a new facility in Shiga, Japan.
This facility is dedicated to the manufacturing of gene therapy products. The presence of such companies with strong product portfolios is anticipated to fuel regional regenerative medicine market growth. Moreover, the governments of some countries in this region are undertaking favorable policies for regenerative medicine.
For instance, in 2019, the South Korean government passed the Act on the Safety and Support of Advanced Regenerative Medical and Advanced Biopharmaceuticals, which allows conditional approval for the commercial sale of phase II completed drugs. Such favorable government initiatives are expected to accelerate the growth of the regenerative medicine market.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific regenerative medicine market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific regenerative medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account